Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
Conditions:   Advanced Solid Tumor;   Non Small Cell Lung Cancer;   Head and Neck Squamous Cell Carcinoma;   Malignant Melanoma;   Renal Cell Carcinoma;   Ovarian Cancer;   Cervical Cancer;   Microsatellite Instability High;   Gastric Cancer;   GastroEsophageal Cancer;   Urothelial Carcinoma;   Mismatch Repair Deficiency
Interventions:   Drug: STK-012;   Drug: Pembrolizumab
Sponsor:   Synthekine
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 28, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments